Cargando…

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease

RationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions. Here, we present a case of idiopathic multicentric Castleman disease in the eighth decade of life. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chrysochoou, Stamatios, Kreft, Andreas, Schneider, Eberhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986409/ https://www.ncbi.nlm.nih.gov/pubmed/35399163 http://dx.doi.org/10.1155/2022/1840589

Ejemplares similares

Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
por: Sitenga, Jenna, et al.
Publicado: (2018)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab
por: van Rhee, Frits, et al.
Publicado: (2020)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
por: van Rhee, Frits, et al.
Publicado: (2015)

Emerging treatments in Castleman disease – a critical appraisal of siltuximab
por: Koff, Jean L, et al.
Publicado: (2016)

POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation
por: Lee, Yong-Moon, et al.
Publicado: (2022)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2015)

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Publicado: (2023)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma
por: Gunathilake, KUIS, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report
por: Han, Ping-Yang, et al.
Publicado: (2020)

Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
por: Ferrero, Simone, et al.
Publicado: (2021)

Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
por: Arakawa, Akira, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
por: Hoffmann, Christian, et al.
Publicado: (2022)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Multicentric Castleman disease with infiltration of eosinophils to the lung
por: Nakai, Shogo, et al.
Publicado: (2021)

A case of acute progressive diffuse interstitial lung disease preceding idiopathic multicentric Castleman disease
por: Nabeya, Daijiro, et al.
Publicado: (2020)

Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab
por: Tabata, Sakiko, et al.
Publicado: (2019)

A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report
por: Strach, Magdalena, et al.
Publicado: (2023)

Idiopathic multicentric castleman’s disease mimicking immunoglobulin G4-related disease responding well to Bortezomib: a case report
por: Peng, Qian, et al.
Publicado: (2023)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q9bhq1k1avidd0ls9vineidr6h